S4C-1

(A278) Mobile online telemonitoring (MOT) in pediatric dialysis patients (P)
Schaefer, Franz (Germany)

11:10

S4C-2

(A185) Analysis of depression and its effect on outcome in adult Indian peritoneal dialysis (PD) patients
Mahajan, Sandeep (India)

11:20

S4C-3

(A413) Prevalence of and factors associated with mini-mental state examination (MMSE) - assessed cognitive function deficit in patients on PD (N)
Fernades, Natalia (Brazil)

11:30

S4C-4

(A576) Effect of self-management strategy on improving compliance to water and salt restriction in anuric CAPD patients (N)
Luo, Su-ping (China)

11:40

S4C-5

(A578) 4 Rs in renal rehabilitation
Ho, Yiu-Wing (Hong Kong)

11:50

S4C-6

(A114) Is a simple 1-item self-rated health useful in predicting mortality among PD patients?
Thong, Melissa (The Netherlands)

12:00

S4C-7

(A498) Anaemia status in patients on PD in the French Peritoneal Dialysis Registry (RDPLF)
Verger, Christian (France)

12:10

S4C-8

(A543) What is the optimal timing of dialysis initiation?
Tang, Sydney (Hong Kong)

12:20

S4C-9

(A84) Sexual dysfunction in peritoneal dialysis patients: a multicenter collaborative study
Lai, Chun-Fu (Taiwan)

S5A-1

(A570) Twenty-five years experience of continuous ambulatory peritoneal dialysis in a single kidney center
Han, Seung-Hyeok (Korea)

15:10

S5A-2

(A146) Outcomes of long-term peritoneal dialysis in Japanese children (P)
Hoshii, Sakurako (Japan)

15:20

S5A-3

(A110) Long term changes in peritoneal membrane function in children on chronic PD (P)
Borzych, Dagmara (Germany)

15:30

S5A-4

(A192) Comparisons of peritoneal dialysis and hemodialysis in elder patients: A Japanese multi-center study
Masakane, Ikuto (Japan)

15:40

S5A-5

(A316) The risk of death on PD is higher with previous HD (N)
Bernardini, Judith (USA)

15:50

S5A-6

(A502) Longitudinal changes in inflammatory status during the first year of hemodialysis (HD) or peritoneal dialysis (PD)
Carrero, Juan (Sweden)

16:00

S5A-7

(A540) Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcomes
Choi, Hoon-Young (Korea)

16:10

S5A-8

(A273) N-ANP and BNP both predict survival in patients on peritoneal dialysis
Rutten, Joost (The Netherlands)

16:20

S5A-9

(A419) The osteoclast inhibitor osteoprotegerin is an independent predictor of survival in end-stage renal disease patients starting peritoneal dialysis
Matsubara, Keisuke (Sweden)

S5B-2

(A190) Conversion of innocent GDPs into toxic counterparts
Kjellstrand, Per (Sweden)

15:40

S5B-3

(A389) Low GDP dialysate protects peritoneum from EMT by amelioration of decreased expression of anti-fibrotic factors in cultured human peritoneal mesothelial cells
Kim, Jung-Hye (Korea)

15:50

S5B-4

(A477) Low glucose/GDP dialysis regimen results in increased mesothelial regeneration and vascular permeability
Van den Born, Jacob (The Netherlands)

16:00

S5B-5

(A89) Effects of icodextrin on the integrin-mediated wound healing of peritoneal mesothelial cells
Tamura, Masahito (Japan)

16:10

S5B-6

(A390) Metabolism of oligosaccharides in end-stage renal disease patients
Garcia-Lopez, Elvia (Sweden)

16:20

S5B-7

(A449) In vitro capillary tubes formation is enhanced by mesothelial cell VEGF secretion after RAGE activation
Grossin, Nicolas (The Netherlands)

S6B-2

(A355) CCL 18: Novel cytokine present in PD fluid and involved in regulation of inflammation and fibrosis in the peritoneal membrane
Ahmad, Sohail (UK)

09:40

S6B-3

(A335) High glucose-induced EMT with decreased expression of anti-fibrotic cytokines is not prevented by HGF and/or BMP-7 treatment in cultured human peritoneal mesothelial cells
Shin, Kyung-Sook (Korea)

09:50

S6B-4

(A581) Correlation between morpho-functional features and mesothelial-to-mesenchymal transition in a series of peritoneal biopsies from short-term peritoneal dialysis patients
Jimenez, Jose (Spain)

10:00

S6B-5

(A154) Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients
Sherif, Ali (Japan)

10:10

S6B-6

(A204) Effects of tamoxifen on epithelial-to-mesenchymal transition (EMT), fibrosis and angiogenesis of mesothelial cells
Selgas, Rafael (Spain)

10:20

S6B-7

(A342) The cellular contribution to effluent K+ and its relation to free water transport during peritoneal dialysis
Coester, Annemieke (The Netherlands)

S6C-1

(A528) The clinical usefulness of novel biocompatible peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration
Choi, Hoon-Young (Korea)

09:10

S6C-2

(A470) Glucose degradation products in PD fluids predict decline of residual renal function
Haag-Weber, Marianne (Germany)

09:20

S6C-3

(A458) Comparison of glucose versus icodextrin based peritoneal dialysis fluid with proteomic techniques in children (P)
Raaijmakers, Renske (The Netherlands)

09:30

S6C-4

(A54) Improved blood pressure control with low-sodium PD fluid
Davies, Simon (UK)

09:40

S6C-5

(A429) Dialytic phosphate removal: A new measure of PD adequacy in APD patients?
Borzych, Dagmara (Germany)

09:50

S6C-6

(A372) Comparative effects of sevelamer hydrochloride (Renagel®) and calcium acetate for the control of serum phosphorus in peritoneal dialysis patients
Fan, Stanley (UK)

10:00

S6C-7

(A58) The management of SHPT in CPD patients with cinacalcet
Finkelstein, Fredric (USA)

10:10

S6C-8

(A72) New onset hyperglycemia in non-diabetic patients started on peritoneal dialysis
Szeto, Cheuk-Chun (Hong Kong)

10:20

S6C-9

(A392) Carbohydrate metabolism disturbances in non-diabetic patients on peritoneal dialysis
Pecoits-Filho, Roberto (Brazil)

S7C-1

(A126) Antibiotic treatment of peritonitis in children: A report of the International Pediatric Peritonitis Registry (IPPR) (P)
Warady, Bradley (USA)

11:10

S7C-2

(A119) Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis
Cheung, Kitty Kit-Ting (Hong Kong)

11:20

S7C-3

(A183) Influence of virulent strains of staph aureus in pathogenesis of exit site infection in peritoneal dialysis
Dasgupta, Mrinal (Canada)

11:30

S7C-4

(A217) Tamoxifen treatment for peritoneal fibrosing syndromes. A comparison to a non-treated historical series
Bajo, Maria (Spain)

11:40

S7C-5

(A234) Omental folding: A novel laparoscopic technique for salvage of PD catheters
Goh, Heng (Malaysia)

11:50

S7C-6

(A299) Nystatin prophylaxis for the prevention of fungal peritonitis in patients receiving CAPD: a single-center experience on 481 patients
Wong, Ping-Nam (Hong Kong)

12:00

S7C-7

(A315) Long term follow up of gentamicin cream at the exit site (N)
Bernardini, Judith (USA)

12:10

S7C-8

(A445) The timing of PD catheter removal in people with unresponsive PD peritonitis
Collins, John (New Zealand)

12:20

S7C-9

(A532) Prospective randomized trial of prophylaxis antibiotic for newly placed peritoneal dialysis to prevent postoperative peritonitis and wound infection
Yu, Xueqing (China)

S8C-2

(A343) The effects of an experimental peritoneal dialysis solution on the peritoneum in an uremic rat model
Zegwaard, Agnes (The Netherlands)

14:55

S8C-3

(A474) COX-2 inhibition largely prevents peritoneal worsening in rat PD model
Van den Born, Jacob (The Netherlands)

15:05

S8C-4

(A530) Effects of overexpression Smad7 on the expression of AQP-1,3 in a rat peritoneal fibrosis model
Yu, Xueqing (China)

15:15

S8C-5

(A77) Smad3 is a key mediator of TGF-β signaling in peritoneal fibrosis in vitro
Duan, Wenjuan (China)

15:25

S8C-6

(A128) Effects of platelet derived growth factor on the peritoneum
Margetts, Peter (Canada)

15:35

S8C-7

(A290) Protective roles of peroxisome proliferator-activated receptor-gamma (PPAR-γ) against peritoneal membrane injury
Kanjanabuch, Talerngsak (Thailand)